Rokos Capital Management LLP Makes New $9.83 Million Investment in Jazz Pharmaceuticals PLC $JAZZ

Rokos Capital Management LLP purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the first quarter, Holdings Channel reports. The institutional investor purchased 52,017 shares of the specialty pharmaceutical company’s stock, valued at approximately $9,833,000.

A number of other institutional investors also recently modified their holdings of the company. Empowered Funds LLC raised its stake in Jazz Pharmaceuticals by 2.6% during the first quarter. Empowered Funds LLC now owns 14,236 shares of the specialty pharmaceutical company’s stock worth $2,691,000 after buying an additional 362 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in Jazz Pharmaceuticals by 9.7% in the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after buying an additional 16,928 shares during the period. Lazard Asset Management LLC boosted its position in Jazz Pharmaceuticals by 199.1% during the first quarter. Lazard Asset Management LLC now owns 42,723 shares of the specialty pharmaceutical company’s stock valued at $8,077,000 after acquiring an additional 28,441 shares during the last quarter. Castleark Management LLC bought a new stake in Jazz Pharmaceuticals during the first quarter valued at $9,214,000. Finally, ABS Direct Equity Fund LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $187,000. 89.14% of the stock is owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the transaction, the director owned 18,449 shares in the company, valued at approximately $4,446,209. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares of the company’s stock, valued at $88,176,020.54. This trade represents a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,098 shares of company stock worth $3,131,906 in the last quarter. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $255.43 on Tuesday. The firm’s 50-day moving average price is $237.89 and its 200-day moving average price is $204.06. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $257.00. The firm has a market capitalization of $16.05 billion, a P/E ratio of -12,765.12, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Truist Financial cut their target price on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Raymond James Financial reaffirmed an “outperform” rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft raised their target price on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $259.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.